Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E69.95 EPS (ttm)1.17 Insider Own0.40% Shs Outstand214.07M Perf Week6.56%
Market Cap17.52B Forward P/E28.54 EPS next Y2.87 Insider Trans-10.74% Shs Float213.18M Perf Month5.41%
Income252.90M PEG1.87 EPS next Q0.49 Inst Own94.70% Short Float3.29% Perf Quarter-4.41%
Sales2.00B P/S8.77 EPS this Y133.20% Inst Trans0.49% Short Ratio5.42 Perf Half Y21.62%
Book/sh9.74 P/B8.40 EPS next Y29.13% ROA9.80% Target Price88.06 Perf Year11.14%
Cash/sh7.39 P/C11.08 EPS next 5Y37.33% ROE13.40% 52W Range57.00 - 88.83 Perf YTD28.70%
Dividend- P/FCF44.70 EPS past 5Y23.80% ROI6.30% 52W High-7.87% Beta1.11
Dividend %- Quick Ratio5.20 Sales past 5Y39.60% Gross Margin96.10% 52W Low43.58% ATR2.56
Employees1367 Current Ratio5.20 Sales Q/Q30.20% Oper. Margin13.50% RSI (14)59.45 Volatility3.34% 3.05%
OptionableYes Debt/Eq0.01 EPS Q/Q342.50% Profit Margin12.70% Rel Volume1.84 Prev Close77.71
ShortableYes LT Debt/Eq0.01 EarningsJul 30 BMO Payout0.00% Avg Volume1.29M Price81.84
Recom2.30 SMA203.87% SMA503.78% SMA20010.21% Volume2,377,956 Change5.31%
May-21-19Initiated Credit Suisse Neutral $75
May-03-19Downgrade Barclays Overweight → Equal Weight $90 → $82
Apr-11-19Initiated Stifel Hold $82
Apr-03-19Downgrade RBC Capital Mkts Outperform → Sector Perform $89
Jan-24-19Upgrade William Blair Mkt Perform → Outperform
Jan-24-19Upgrade Gabelli & Co Hold → Buy $105
Jan-16-19Downgrade UBS Buy → Neutral
Jan-03-19Upgrade Guggenheim Neutral → Buy
Oct-22-18Upgrade Raymond James Outperform → Strong Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $73
Sep-25-18Initiated Leerink Partners Mkt Perform
Aug-15-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Aug-01-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-26-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Jun-11-18Upgrade Evercore ISI In-line → Outperform
Apr-09-18Reiterated Credit Suisse Outperform $145 → $78
Apr-09-18Downgrade Gabelli & Co Buy → Hold
Apr-06-18Downgrade William Blair Outperform → Mkt Perform
Apr-06-18Downgrade Guggenheim Buy → Neutral
Jun-17-19 01:30PM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch +5.31%
01:10PM  2 Rallying Pharma Stocks Roping In Option Bulls Schaeffer's Investment Research
Jun-15-19 03:25AM  Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo Business Wire
Jun-13-19 09:32PM  Heres What Hedge Funds Think About Incyte Corporation (INCY) Insider Monkey
05:05PM  Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I Zacks
09:31AM  Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock Zacks
08:24AM  Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study Zacks
Jun-12-19 08:33AM  Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer Zacks
Jun-07-19 04:43PM  Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend traders to sell the rally Yahoo Finance Video
05:00AM  9 interesting things heard during BIO 2019 (Photos) American City Business Journals
Jun-06-19 03:26PM  Incyte Begins Phase III Study for Treatment of Duct Cancer Zacks
Jun-05-19 09:00AM  Celgene (CELG) Presents Data on Pipeline Candidates at ASCO Zacks
Jun-04-19 10:17AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
07:30AM  Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as a First-Line Therapy for Cholangiocarcinoma Business Wire
Jun-03-19 11:52AM  Novartis (NVS) Announces Various Data Presentations at ASCO Zacks
01:45AM  New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib Business Wire
Jun-01-19 11:37AM  The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace Benzinga
May-30-19 04:51PM  Mesoblast Starts Rolling BLA Submission for Remestemcel-L Zacks
09:31AM  Why Is Incyte (INCY) Down 1.7% Since Last Earnings Report? Zacks
May-29-19 10:22AM  Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion Zacks -5.10%
May-28-19 09:06AM  The Zacks Analyst Blog Highlights: Medtronic, TJX, Deere, Incyte and Netapp Zacks
07:45AM  FDA approves Incyte's Jakafi as graft-versus-host disease therapy American City Business Journals
06:30AM  BriaCells Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-27-19 09:17AM  Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi Zacks
May-26-19 05:03PM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-24-19 02:50PM  Incyte's Jakafi gets FDA approval to treat Graft vs Host Disease Reuters
02:20PM  Top Stock Reports for Medtronic, TJX Companies & Deere Zacks
02:14PM  Incyte's Jakafi wins FDA nod to treat complication of stem cell transplant Reuters
01:43PM  FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease Business Wire
May-23-19 08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
May-22-19 01:03PM  FDA to rule this week on Incyte's bid for wider use of Jakafi American City Business Journals
May-21-19 08:46AM  Merck's Keytruda Fails in Late-Stage Breast Cancer Study Zacks
May-20-19 02:15PM  Why I Like Incyte Corporation (NASDAQ:INCY) Simply Wall St.
07:30AM  Data from Incytes Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology Business Wire
May-18-19 09:50AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
May-16-19 12:00PM  Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA Business Wire
May-14-19 07:08AM  Here are Mondays worst stock-market performers as U.S.-China trade dispute escalates MarketWatch
May-13-19 06:30AM  BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders GlobeNewswire -6.11%
May-09-19 08:00AM  Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors GlobeNewswire
May-08-19 09:48AM  Why Incyte Stock Lost 11% in April Motley Fool
May-02-19 09:31PM  Edited Transcript of INCY earnings conference call or presentation 30-Apr-19 12:00pm GMT Thomson Reuters StreetEvents
11:18AM  The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex Zacks
08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
May-01-19 11:52AM  Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates Zacks
Apr-30-19 07:00PM  Top Biotech Stocks for February 2019 Investopedia
05:35PM  Incyte Corp (INCY) Q1 2019 Earnings Call Transcript Motley Fool
04:09PM  This Biotech Stock Just Topped Expectations And Became Profitable Investor's Business Daily
03:18PM  5 Biotech Stocks for a Long-Lived Portfolio InvestorPlace
10:10AM  Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y Zacks
07:44AM  Incyte: 1Q Earnings Snapshot Associated Press
07:00AM  Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs Business Wire
03:05AM  Incyte Earnings, Revenue Beat in Q1 Investing.com
Apr-29-19 06:42PM  Incyte Expected to Earn 29 Cents a Share TheStreet.com
06:14PM  Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings? Zacks
04:14PM  Why Novartis Earnings Provided A Bullish Signal For This Biotech Stock Investor's Business Daily
08:25AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
Apr-26-19 04:07PM  Will HIV Franchise Sales Drive Gilead's (GILD) Q1 Earnings? Zacks
02:01PM  Is a Beat in Store for Glaxo (GSK) This Earnings Season? Zacks
Apr-25-19 09:42AM  Exelixis (EXEL) to Report Q1 Earnings: What's in Store? Zacks
09:27AM  The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences Zacks
09:26AM  The Zacks Analyst Blog Highlights: CommScope, Incyte, Cigna, Columbia Sportswear and Synopsys Zacks
Apr-24-19 04:32PM  What's in Store for Vertex (VRTX) This Earnings Season? Zacks
12:06PM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
11:43AM  Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock? Zacks
09:15AM  Solid Earnings Boost S&P, NASDAQ to New Closing Highs Zacks
09:11AM  5 Biotech Stocks Defying the Medicare-for-All Scare Zacks
09:04AM  Can S&P 500 and Nasdaq Sustain Record Run? 5 Top Picks Zacks
Apr-23-19 10:59AM  Amgen (AMGN) to Report Q1 Earnings: What's in the Cards? Zacks
10:44AM  What's in the Cards for AstraZeneca (AZN) in Q1 Earnings? Zacks
10:32AM  Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
09:27AM  The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap Zacks
Apr-22-19 11:08AM  Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store? Zacks
10:33AM  Is a Beat in Store for AbbVie (ABBV) This Earnings Season? Zacks
10:17AM  Biogen (BIIB) to Report Q1 Earnings: What's in the Cards? Zacks
09:11AM  5 Must-Buy Stocks Amid Exaggerated Economic Slowdown Zacks
Apr-19-19 11:53AM  Should Incyte (NASDAQ:INCY) Be Disappointed With Their 56% Profit? Simply Wall St.
09:27AM  Health-care drama has now spread to biopharma stocks MarketWatch
Apr-12-19 11:08AM  Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group Zacks
Apr-11-19 09:46AM  Concert Pharma Initiates Early-Stage Schizophrenia Study Zacks
08:00AM  Incyte to Report First Quarter Financial Results Business Wire
Apr-08-19 03:09PM  Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling MarketWatch
Apr-03-19 02:21PM  Puts Active After RBC Downgrades Incyte Stock Schaeffer's Investment Research
Apr-02-19 02:58PM  BriaCell Announces Clinical Trial Collaboration Agreement with Incyte GlobeNewswire
Apr-01-19 01:30PM  Did Hedge Funds Drop The Ball On Incyte Corporation (INCY) ? Insider Monkey
07:00AM  Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019 GlobeNewswire
Mar-16-19 09:30AM  Why Is Incyte (INCY) Up 1.7% Since Last Earnings Report? Zacks
Mar-14-19 10:55AM  Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:45AM  Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica Zacks
Mar-13-19 10:55AM  10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run Zacks
09:45AM  4 Toxic Stocks to Abandon or Sell Short for Solid Gains Zacks
Mar-08-19 01:40PM  Why Incyte Corporation (NASDAQ:INCY) Is A Financially Healthy Company Simply Wall St.
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos
06:42AM  Pullback Strategies: 10 Stocks That Could Fall the Fastest Investopedia
Mar-05-19 08:42AM  Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda Zacks
05:00AM  Incyte- Insights into Small Molecule Drugs MoneyShow
Mar-01-19 07:00AM  New Research Coverage Highlights Nasdaq, Constellation Brands, Incyte, IMAX, HNI, and Frank's International N.V Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-28-19 10:30AM  Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019 Business Wire
08:00AM  Data from Incytes Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019 Business Wire
Feb-27-19 09:27AM  Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica Zacks
07:25AM  3 Big Stock Charts for Wednesday: Cabot Oil & Gas, Incyte and Sempra Energy InvestorPlace
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SWAIN PAULA JEVP, Human ResourcesApr 01Option Exercise18.3210,000183,20044,731Apr 02 04:51 PM
SWAIN PAULA JEVP, Human ResourcesApr 01Sale87.0110,000870,10036,513Apr 02 04:51 PM
SWAIN PAULA JEVP, Human ResourcesMar 01Option Exercise18.3210,000183,20046,513Mar 05 04:45 PM
SWAIN PAULA JEVP, Human ResourcesMar 01Sale86.6810,000866,80036,513Mar 05 04:45 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Option Exercise2.8040,000112,00029,288,793Feb 27 05:19 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Option Exercise18.3210,000183,20041,124Feb 05 04:36 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Sale81.1910,000811,90031,124Feb 05 04:36 PM
Flannelly Barry PEVP & General Manager USJan 28Sale80.001,00080,0008,944Jan 30 04:22 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Option Exercise17.7915,354273,14849,763Jan 22 06:04 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Sale77.6115,3541,191,62434,409Jan 22 06:04 PM
Trower PaulPrincipal Accounting OfficerJan 15Option Exercise17.795,813103,41319,713Jan 17 04:15 PM
Trower PaulPrincipal Accounting OfficerJan 15Sale75.005,813435,97513,900Jan 17 04:15 PM
Flannelly Barry PEVP & General Manager USJan 08Sale75.561,714129,5109,944Jan 10 04:11 PM
Trower PaulPrincipal Accounting OfficerJan 07Option Exercise17.799,187163,43723,359Jan 08 04:42 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Option Exercise17.7910,000177,90045,217Jan 08 04:46 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Sale75.0010,000750,00035,217Jan 08 04:46 PM
Trower PaulPrincipal Accounting OfficerJan 07Sale75.009,187689,02514,172Jan 08 04:42 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Option Exercise18.3230,000549,60062,324Jan 08 04:37 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Sale70.0030,0002,100,00032,324Jan 08 04:37 PM
BIENAIME JEAN JACQUESDirectorNov 08Buy68.771,00068,7656,668Nov 09 04:21 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Option Exercise18.3210,000183,20042,324Oct 05 04:29 PM
Trower PaulPrincipal Accounting OfficerOct 03Option Exercise17.7910,000177,90024,172Oct 05 04:30 PM
Trower PaulPrincipal Accounting OfficerOct 03Sale70.0010,000700,00014,172Oct 05 04:30 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Sale70.0010,000700,00032,324Oct 05 04:29 PM
Flannelly Barry PEVP & General Manager USOct 03Sale70.001,00070,00012,427Oct 05 04:23 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Option Exercise18.3210,000183,20042,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Sale73.2110,000732,10032,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Option Exercise18.3210,000183,20042,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Sale70.0010,000700,00032,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Option Exercise18.3210,000183,20042,963Jul 11 04:41 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Sale71.1110,000711,10032,963Jul 11 04:41 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 09Sale71.3460643,2328,103Jul 11 04:39 PM